KAZIA THERAPEUTICS LTD business relationships

Companies named in KAZIA THERAPEUTICS LTD’s 20-F filed 2025-11-07, and public companies whose annual reports name KAZIA THERAPEUTICS LTD. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.4 / 10
AI naming: 70 / 100
Agent readiness: 0 / 100
AI adoption: 0 / 100

Named in KAZIA THERAPEUTICS LTD’s annual report 5

Roche GroupLicensor7.7
“In October 2016, the Company entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway.” SEC filing
Sanofi (SNY)Licensee6.7
“EVT801 was originally discovered by Sanofi SA and was licensed to Evotec SE as part of a broader transaction.” SEC filing
Evotec SE (EVO)Licensee5.5
“EVT801 was originally discovered by Sanofi SA and was licensed to Evotec SE as part of a broader transaction.” SEC filing
Evotec SE (EVO)Licensor5.5
“License Agreement with Evotec SE” SEC filing
Genentech, IncLicensor4.7
“License Agreement with Genentech Inc.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.